Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 4, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Cryo-Ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer.

Herbert Lepor1, Jared Fiske1, Majlinda Tafa1

  • 1Department of Urology, NYU Grossman School of Medicine, New York, NY 10017.

Urology
|June 2, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Indigo Carmine Visualization Duration in Urine: A Randomized Kinetics Study.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Association of plasma biomarkers with amyloid and tau PET in pre-dementia stages.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

How urology can embrace the patient-centric precision focal therapy approach for localized prostate cancer.

Nature reviews. Urology·2026
Same author

Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: Toxicity.

Advances in radiation oncology·2026
Same author

Impaired LC-NE System-A Novel Molecular Mechanism Underlying Health Disparity and Increased Prevalence of Alzheimer's Disease Among African Americans.

Diagnostics (Basel, Switzerland)·2026
Same author

Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.

European radiology·2026

Focal cryo-ablation (FCA) shows promising 7-year oncological outcomes for intermediate risk prostate cancer. Recurrence-free survival was 70.31% at 7 years, with African American race being a predictor of recurrence.

Area of Science:

  • Urology
  • Oncology
  • Medical Imaging

Background:

  • Focal cryo-ablation (FCA) is an emerging treatment for localized prostate cancer.
  • Intermediate favorable risk prostate cancer (IFRPCa) requires effective focal therapies.
  • Long-term oncological outcomes of FCA for IFRPCa are not well-established.

Purpose of the Study:

  • To evaluate the 7-year oncological outcomes of FCA in men with IFRPCa.
  • To assess the recurrence rates and survival following FCA treatment.
  • To identify predictors of cancer recurrence after FCA.

Main Methods:

  • A prospective longitudinal study enrolled 276 men with unilateral IFRPCa treated with FCA.
  • Eligibility criteria included specific MRI findings and no high-grade contralateral disease.

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Thermal Ablation for the Treatment of Abdominal Tumors
07:16

Thermal Ablation for the Treatment of Abdominal Tumors

Published on: March 7, 2011

Related Experiment Videos

Last Updated: Jun 4, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Thermal Ablation for the Treatment of Abdominal Tumors
07:16

Thermal Ablation for the Treatment of Abdominal Tumors

Published on: March 7, 2011

  • Oncological surveillance involved PSA and MRI testing, with biopsies for rising PSA or suspicious imaging.

    • Main Results:

    • At 7 years, 39 (14.1%) men experienced clinically significant prostate cancer (csPCa) recurrence.
    • Recurrence-free survival rates at 3, 5, and 7 years were 90.20%, 78.36%, and 70.31%, respectively.
    • African American race was the sole independent predictor of csPCa recurrence; no cancer mortalities occurred.

    Conclusions:

    • FCA is a viable treatment option for selected IFRPCa patients with specific MRI characteristics.
    • The study supports FCA for focal IFRPCa without extra-capsular extension or high-grade contralateral disease.
    • Long-term surveillance confirms the safety and efficacy of FCA in this patient cohort.